2017 American Association for Cancer Research (AACR) Annual Meeting

Schedule of DCTD Presentations

Several members of DCTD's staff will present information at the AACR Annual Meeting in Washington, DC between April 1-5, 2017.

• Oral Presentations
• Poster Presentations
• Meet-the-Expert Presentations
• DCTD Staff Kiosk Schedule

Oral Presentations

Time	Title	Presenter	Location
Saturday, April 1
8:30 - 8:50 AM	Utility of Patient-derived Xenograft Models to Mirror Precision Oncology Clinical Trials	James H. Doroshow, MD Director, DCTD	Room 151, Level 1, Washington Convention Center
8:30 - 8:50 AM	Clinical Trials Design Workshop - Part 1: Clinical Trials for Targeted Therapies	Jeffrey Moscow, MD, Cancer Therapy Evaluation Program	Room 145, Level 1, Washington Convention Center
9:00 - 9:20 AM	Pharmacodynamic Modeling to Predict Biologically Effective Drug Dosing	Ralph E. Parchment, PhD, Office of the Director	Room 151, Level 1, Washington Convention Center
Sunday, April 2
2:00 - 4:00 PM	Women in Cancer Research Council Meet and Greet	S. Percy Ivy, MD, Cancer Therapy Evaluation Program	AACRcentral (Booth 1125), WICR Resource Center, Lower Level, Washington Convention Center
Monday, April 3
1:00 - 1:45 PM	NCI Cancer Imaging Program Informatics Integration	Janet F. Eary, MD, Cancer Imaging Program	Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DC
Tuesday, April 4
7:00 - 8:00 AM	Utilizing "Normal" Genomic Data from the GTEx Project in Cancer Research	Helen Moore, PhD, and Abhi Rao, PhD, Cancer Diagnosis Program	Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DC
10:30 AM - 12:30 PM	Funding Opportunities for Cancer Research at Multiple National Institutes of Health (NIH) Institutes and Centers with NIH Experts	Julia T. Arnold, PhD, Translational Research Program	Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DC
12:30 - 2:30 PM	Technology Transfer and Intellectual Property: Career Opportunities for Researchers	Jason V. Cristofaro, JD, PhD, Office of the Director	Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DC
Wednesday, April 5
10:30 AM - 12:00 PM	The NCI Best Practices for Biospecimen Resources: 2016 revised recommendations	Abhi Rao, PhD, Cancer Diagnosis Program	Room 143, Level 1, Washington Convention Center
11:15 - 11:40 AM	Tumor Models as Novel Diagnostics: Finding Drugs that Work	James H. Doroshow, MD, Director, DCTD	Room 202, Level 2, Washington Convention Center

Poster Presentations

Time	Title	Location
Sunday, April 2
1:00 PM - 5:00 PM	Comparison of the response of the NCI60 NSCLC panel with the response of patient-derived NSCLC lines to approved and investigational agents	Section 15; Abstract 348/4
1:00 PM - 5:00 PM	A clinically validated multiplex immunofluorescence assay for the quantitative assessment of changes in EMT phenotypes in FFPE tumor tissues in response to cancer therapeutics	Section 40; Abstract 845/4
1:00 PM - 5:00 PM	Biospecimen and data resources for cancer research from NCI's BPV program	Section 16; Abstract 376/2
Monday, April 3
8:00 AM - 12:00 PM	Longitudinal expression response of glycosylation related genes, regulators, and targets in cancer cell lines treated with eleven anti-tumor agents	Section 24; Abstract 1557/6
8:00 AM - 12:00 PM	The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, OT-82, exhibits in vitro and in vivo efficacy against patient-derived xenograft models of high risk acute lymphoblastic leukemia	Section 42; Abstract 1942/14
1:00 - 5:00 PM	Analysis of APOBEC3A and APOBEC3B mutational signatures using next-generation sequencing data from cancer cell lines	Section 24; Abstract 2590/9
Tuesday, April 4
8:00 AM - 12:00 PM	The National Cancer Institute's patient-derived models repository (PDMR)	Section 37; Abstract 3840/6
8:00 AM - 12:00 PM	A clinical pharmacodynamic biomarker assay that distinguishes potentially repairable, cytotoxic drug-induced DNA double strand breaks (DSBs) from DSBs associated with apoptotic cell death	Section 2; Abstract 3072/10
1:00 - 5:00 PM	Effects of epigenetic agents on methylation of DNA in vitro and in vivo, as measured with stable isotopically labeled methionine	Section 15; Abstract 4351/7
1:00 - 5:00 PM	Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations	Section 29; Abstract 4678/9
1:00 - 5:00 PM	Establishing a platform for the generation of organoids from diverse tumor types as part of the NCI patient-derived models (PDM) initiative	Section 39; Abstract 4827/17
1:00 - 5:00 PM	Small cell lung carcinoma (SCLC) cell line screen of standard of care (etoposide/carboplatin) plus a third agent	Section 39; Abstract 4831/21
Wednesday, April 5
8:00 AM - 12:00 PM	Disruption of DNA methyltransferase (DNMT) 1 confers resistance to DNMT inhibitors in human colorectal cancer cells	Section 2; Abstract 5081/26

Meet-the-Expert Presentations

NCI Exhibit Booth # 1407

Time	Topic	Presenter
Sunday, April 2
3:00 - 3:15 PM	Publically Available Biospecimen Resources Supported by the Cancer Diagnosis Program	Rodrigo Chuaqui, MD, Irina Lubensky, MD, Joanne Demchok, MS, Cancer Diagnosis Program
3:15 - 3:30 PM	Newly Revised NCI Best Practices for Biospecimen Resources	Helen Moore, PhD, Cancer Diagnosis Program, Rihab Yassin, PhD, Division of Cancer Biology
Monday, April 3
1:15 - 1:45 PM	Everything You Wanted to Know about the NCI-Pediatric MATCH Trial	Nita Seibel, MD, Cancer Therapy Evaluation Program
3:30 - 4:00 PM	The NCI Formulary: A Cancer Moonshot Initiative	Jason Cristofaro, JD, PhD, Office of the Director
4:15 - 4:30 PM	Patient-derived Xenograft Model Repository	Yvonne Evrard, PhD, Developmental Therapeutics Program
4:30 - 4:45 PM	Small Cell Lung Cancer Carcinoma Cell Line Screen of Etoposide/Carboplatin Plus a Third Agent	Beverly Teicher, PhD, Developmental Therapeutics Program
Tuesday, April 4
2:00 - 2:15 PM	Cancer Biomarker Assay Development & Funding Opportunities: A Cancer Diagnosis Program Initiative	Aniruddha Ganguly, PhD, Cancer Diagnosis Program
2:15 - 2:30 PM	NCI Pharmacodynamics Biomarker Program	Katherine Ferry-Galow, PhD, Pharmacodynamic Assay, Development and Implementation Section
2:45 - 3:00 PM	Translational Research at the National Cancer Institute: Specialized Programs of Research Excellence (SPOREs)	Igor Kuzmin, PhD, Translational Research Program
3:00 - 3:15 PM	NCI Cancer Complementary and Alternative Medicine Programs	Libin Jia, MD, Office of Cancer Complementary and Alternative Medicine

DCTD Kiosk Activity: NCI Exhibit Booth # 1407

DCTD staff will interact with prospective and present grantees, provide program overview, distribute program information and funding opportunities, and provide guidance to prepare grant applications.

Time	DCTD Staff
Sunday, April 2
1:00 - 3:00 PM	Aniruddha Ganguly, PhD, Cancer Diagnosis Program
3:00 - 5:00 PM	Katherine Ferry-Galow, PhD, Pharmacodynamic Assay, Development and Implementation Section
Monday, April 3
9:00 - 11:00 AM	Sherry Ansher, PhD, Cancer Therapy Evaluation Program
11:00 AM - 1:00 PM	Beverly Teicher, PhD, Developmental Therapeutics Program
1:00 - 3:00 PM	Julia Arnold, PhD, Translational Research Program Yvonne Evrard, PhD, Developmental Therapeutics Program
3:00 - 5:00 PM	Steve Nothwehr, PhD, Translational Research Program
Tuesday, April 4
9:00 - 11:00 AM	Abhi Rao, PhD, Cancer Diagnosis Program Ping Guan, PhD, Cancer Diagnosis Program
11:00 AM - 1:00 PM	Igor Kuzmin, PhD, Translational Research Program
1:00 - 3:00 PM	Vikram Devgan, PhD, MBA, Cancer Therapy Evaluation Program
3:00 - 5:00 PM	Magdalena Thurin, PhD, Cancer Diagnosis Program
Wednesday, April 5
9:00 - 10:30 AM	Nina Lukinova, PhD, Cancer Diagnosis Program
10:30 AM - 12:00 PM	Aniruddha Ganguly, PhD, Cancer Diagnosis Program